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Introduction {#sec001}
============

*Streptococcus pneumoniae* is a major human pathogen responsible for a spectrum of diseases, including pneumonia and sepsis, causing illness and death in millions of individuals. Susceptibility to pneumococcal infections is associated with genetic components that strongly influence the host responses to infection, but little is known about the causal gene(s). Our groups previously used mouse models of respiratory disease as tools to dissect the genetic factors that influence the host immune responses to invasive pneumococcal disease \[[@ppat.1008464.ref001]\]. These previous studies found a clear spectrum of susceptibility and resistance to pneumococcal infections in inbred mouse strains. While resistant BALB/c mice showed a median survival time of \> 168 hours after intranasal infection, and some other strains such as C57BL/6 or DBA/2 had intermediate survival times of 70 to 85 hours, the CBA/Ca strain was highly susceptible, with a survival time of only 27 hours after intranasal infection with *S*. *pneumoniae* \[[@ppat.1008464.ref001]\]. The high susceptibility of CBA/Ca mice was associated with a high bacteremia, whereas no bacteria were detected in the blood of resistant BALB/c mice.

In order to map the responsible genetic locus for susceptibility or resistance to *S*. *pneumoniae* infection, intercrosses of the BALB/c and CBA/Ca strains were done and F2 mice were used to map a major locus controlling the development of bacteremia and survival after intranasal infection with *S*. *pneumoniae*. We identified this major locus on chromosome (Chr) 7, near D7Mit77, which showed high logarithm of the odds (LOD) scores associated with survival time (LOD = 6.3) and bacteremia (LOD = 4.6) \[[@ppat.1008464.ref002]\]. The quantitative trait locus (QTL) on Chr. 7 was named *S*. *pneumoniae infection resistant 1* (*Spir1*). This locus identified on Chr 7 covered 11 Mb and contained about 250 genes.

We also performed genome-wide association studies (GWAS) to map genetic loci associated with susceptibility to pneumococcal infections in 26 inbred mouse strains. Four candidate QTLs were identified, on Chr. 7, 13, 18 and 19 \[[@ppat.1008464.ref003]\]. Notably, the QTL on Chr. 7 was located within the *Spir1* locus, previously identified by the linkage study in BALB/c x CBA/Ca F2 mice. Within the hundreds of the genes in the *Spir1* QTL, only 22 genes showed phenotype-associated polymorphisms.

Now we report that a natural mutation in the *Cd22* gene within *Spir1* is the major explanation of the susceptibility of CBA/Ca mice to intranasal *S*. *pneumoniae* infection. CD22 (Siglec-2) is a B-lymphocyte-specific receptor and negatively regulates B cell receptor signaling. CD22 is implicated in B cell survival and proliferation and in induction of B cell tolerance and control of susceptibility to autoimmune diseases \[[@ppat.1008464.ref004]--[@ppat.1008464.ref006]\]. We found that the natural mutation in the *Cd22* gene of CBA/Ca mice causes a stop codon in the first immunoglobulin-like domain of CD22, leading to a non-functional protein. Also, CD22-deficient mice on a pure C57BL/6 background (CD22-/- mice) showed the same susceptibility. We demonstrated a strong reduction of B cells in the lungs of CBA/Ca and CD22-/- mice after pneumococcal lung infections, in contrast to innately resistant mice. Importantly, GM-CSF producing innate response activator (IRA) B cells were strongly diminished in the lungs of mice lacking functional CD22. This shows an unexpected, and novel, role of the B cell protein CD22 in immunity to pneumococci.

Results {#sec002}
=======

A polymorphism in the *Cd22* gene of CBA/Ca mice leads to lack of the CD22 protein {#sec003}
----------------------------------------------------------------------------------

As observed previously (1) the mouse strain CBA/Ca shows a strong susceptibility to intranasal infections with *S. pneumoniae*. While all CBA/Ca mice died within 36 hours of intranasal infections, all BALB/c mice survived more than 168 hours ([Fig 1A](#ppat.1008464.g001){ref-type="fig"}). This led to a strong disease score in CBA/Ca mice but no disease signs in BALB/c mice ([Fig 1B](#ppat.1008464.g001){ref-type="fig"}). While the number of bacteria was controlled in the lungs of BALB/c mice after 24 hours, this did not occur in CBA/Ca mice ([Fig 1C](#ppat.1008464.g001){ref-type="fig"}), coinciding with high bacteremia in the blood of CBA/Ca mice ([Fig 1D](#ppat.1008464.g001){ref-type="fig"}). In order to determine the responsible locus, we sequenced the *Spir1* locus and within the locus observed 40 SNPs in the *Cd22* gene differing between BALB/c and CBA/Ca genomes. These were synonymous and non-synonymous mutations but, most notably, a SNP in the CBA/Ca *Cd22* gene at position 7:30,877,586 was predicted to introduce a stop codon (TAA). The tool, *Variant Effect Predictor*, provided at the *Ensembl* website ([www.ensembl.org](http://www.ensembl.org/)), was used to investigate variations between the sequences of 37 inbred mouse strains within the database. None of the 37 inbred strains in *Ensembl* had the SNP found in CBA/Ca ([S1 Fig](#ppat.1008464.s001){ref-type="supplementary-material"}).

![CBA/Ca mice show a strong susceptibility after intranasal *S*. *pneumoniae* infections, when compared to BALB/c mice.\
A) Survival of infected mice monitored for 7 days. B) Disease scores. C) Number of bacteria per mg of lung tissue or D) per ml of blood (D). Data represent mean values ± SEM. Statistics were done with Log-rank test (for A), two-tailed *t* test (for B) and two-way ANOVA followed by Bonferroni post-test (for C, D). \* = p\<0.05, \*\* = p\<0.01, \*\*\* = p\<0.001. A) and B): 10 animals per group; C) and D): more than 4 animals per group. Results are representative of 2 independent experiments.](ppat.1008464.g001){#ppat.1008464.g001}

The SNP in the *Cd22* gene (C-\>T) of CBA/Ca, that results in a stop codon, is located in exon 4 of the *Cd22* gene, which encodes for the first CD22 Ig domain that contains the ligand-binding site. The SNP is located within the codon for amino acid 99 (Q) and the resulting stop codon is predicted to prevent synthesis of the bulk of the 130kd protein ([Fig 2A](#ppat.1008464.g002){ref-type="fig"}). If the 98-amino acid N-terminus of the CD22 was synthesised, it was predicted that it would not be a stable product. CD22 has 7 extracellular Ig domains and its function is dependent on its membrane position \[[@ppat.1008464.ref006]\]. To confirm the loss of the CD22 protein from B cells of CBA/Ca mice, splenic cells and lung cells were stained with anti-CD22 monoclonal antibody OX-97, before and after intranasal *S*. *pneumoniae* infection. While BALB/c mice expressed CD22 on their splenic and lung B cells, whether infected or not, CD22 was totally undetected on B cells from noninfected and infected CBA/Ca mice ([Fig 2B](#ppat.1008464.g002){ref-type="fig"}). The lack of CD22 on B cells of CBA/Ca mice was confirmed with another CD22-specific monoclonal antibody, Cy34.1 ([S2 Fig](#ppat.1008464.s002){ref-type="supplementary-material"}). Because both monoclonals bind to the second Ig-like domain of CD22 (d2 in [Fig 2A](#ppat.1008464.g002){ref-type="fig"}) \[[@ppat.1008464.ref007], [@ppat.1008464.ref008]\], it can be concluded that CBA/Ca mice lack the CD22 protein on the B cell surface.

![CBA/Ca mice carry a mutation in *Cd22* which leads to lack of CD22 expression on B cells.\
A) Structure of the *Cd22* gene. The highlighted DNA and amino acid sequence of exon 4 shows the sequence of most mouse strains and the mutation found in CBA/Ca mice (C-\>T) causing an introduction of a stop codon. B) Flow cytometric analysis of splenocytes and lung cells from BALB/c and CBA/Ca mice stained for CD19 and CD22 (Mab OX-97) in the absence of infection and after intranasal infection with *S*. *pneumoniae*.](ppat.1008464.g002){#ppat.1008464.g002}

CD22-deficient mice show a high susceptibility to *S*. *pneumoniae* infections {#sec004}
------------------------------------------------------------------------------

CBA/Ca mice, which lack CD22 protein, showed a high susceptibility to *S*. *pneumoniae* infections \[[@ppat.1008464.ref001]\]. To determine whether this phenotype is directly caused by the loss of the CD22 protein, CD22-deficient mice on a pure C57BL/6 background and C57BL/6 control mice were infected with *S*. *pneumoniae* and monitored for 7 days.

After pneumococcal infection, very different survival rates were observed between C57BL/6 (CD22-positive) and mice with a CD22-deficiency on a C57BL/6 background. The survival rate of the CD22-/- group was much lower than the control group (p\<0.001), with 100% of the CD22-deficient mice reaching the experimental endpoint by 72h post-infection, whereas 56% of the control mice survived to the end of the experiment, at 168h ([Fig 3A](#ppat.1008464.g003){ref-type="fig"}). The median survival time of the CD22-deficient mice that survived was 45h, while the C57BL/6 that succumbed had longer survival time of 82h (p\<0.001). Following the infection, the five C57BL/6 mice that survived showed only very mild disease signs. The increased susceptibility of the CD22-deficient mice was reflected in the early appearance of signs of disease and the rapid progression of the disease score ([Fig 3B](#ppat.1008464.g003){ref-type="fig"}).

![Strong susceptibility of CD22-/- mice to *S*. *pneumoniae* infections, when compared to C57BL/6 (CD22+/+) mice.\
A) Survival of infected mice monitored for 7 days. B) Disease scores. Number of bacteria per mg of lung tissue (C), per ml of blood (D) or per mg of spleen tissue (E). Data represent mean values ± SEM. Statistics were done with Log-rank test (for A), two-tailed *t* test (for B) and two-way ANOVA followed by Bonferroni post-test (for D, E). \* = p\<0.05, \*\* = p\<0.01, \*\*\* = p\<0.001. A) and B): 9--10 animals per group; C-E): 5 animals per group. Significant increase of number of pneumococci in the lung tissue of CD22-/- and control mice (Figure C), between 0 and 12 hours p.i. (p\<0.05); significant increase of CFU numbers in the blood of CD22-/- mice (p\<0.01) (Figure D); and significant increase of CFU numbers in the spleen of CBA/Ca mice (p\<0.001). Results are representative of 2 independent experiments.](ppat.1008464.g003){#ppat.1008464.g003}

Next, the progress of pneumococcal disease in CD22-/- mice and controls was investigated in an experiment that determined pneumococcal numbers in the lung, blood and spleen at over 48 hours post-infection. Although there was a tendency of higher CFUs in the lungs of CD22-/- mice, there were no significant differences (p\>0.05) in the number of bacteria in the lungs of CD22-/- mice and the control group, at any of the time points ([Fig 3C](#ppat.1008464.g003){ref-type="fig"}). In contrast, there was a strong dissemination of bacteria to the blood ([Fig 3D](#ppat.1008464.g003){ref-type="fig"}) and spleen ([Fig 3E](#ppat.1008464.g003){ref-type="fig"}) of CD22-/- mice. The numbers of bacteria progressively increased in the blood and spleen between 12 and 48 hours in CD22-/- mice. In contrast, hardly any bacteria were detected either in the blood or spleen of the C57BL/6 (CD22+/+) mice ([Fig 3D and 3E](#ppat.1008464.g003){ref-type="fig"}).

After *S*. *pneumoniae* infection, CD22-deficient mice have impaired B cell populations in the lung {#sec005}
---------------------------------------------------------------------------------------------------

After intranasal infection with *S*. *pneumoniae*, CBA/Ca mice showed impaired B cell numbers in the lung, when compared to the BALB/c strain of mice ([S3A Fig](#ppat.1008464.s003){ref-type="supplementary-material"}). In the spleen the two strains show no difference in B cell numbers up to 12 hours after infection, but at 24h after the infection higher B cell numbers were detected in CBA/Ca ([S3B Fig](#ppat.1008464.s003){ref-type="supplementary-material"}). The cellular composition of immune cells infiltrating the lungs was analysed in more detail after *S*. *pneumoniae* infection of CD22-/- and C57BL/6 (CD22+/+) mice ([Fig 4](#ppat.1008464.g004){ref-type="fig"}). Numbers of neutrophils ([Fig 4A](#ppat.1008464.g004){ref-type="fig"}) and eosinophils ([Fig 4B](#ppat.1008464.g004){ref-type="fig"}) increased over time after infection, but there were no consistent differences between the two mouse strains. T cells and alveolar macrophages increased in numbers and there were also no consistent differences between CD22-/- and C57BL/6 mice ([Fig 4C and 4D](#ppat.1008464.g004){ref-type="fig"}). However, numbers of conventional B cells, as well as B1a cells were highly elevated in the lungs of C57BL/6 mice at each time point following infection, but much less so in CD22-/- mice ([Fig 4E and 4F](#ppat.1008464.g004){ref-type="fig"}). Consequently, numbers of both conventional B2 cells ([Fig 4E](#ppat.1008464.g004){ref-type="fig"}), as well as of B1a cells ([Fig 4F](#ppat.1008464.g004){ref-type="fig"}), were significantly higher in the C57BL/6 lungs compared to the CD22-/- at all time points. In contrast, B2 and B1a cell numbers were unchanged in the spleen of both strains after infection, with the exception of lower B2 cells in CD22-/- mice at 48 hours ([Fig 4G and 4H](#ppat.1008464.g004){ref-type="fig"}). From earlier studies it is known that there are no differences in B cell numbers in uninfected CD22-/- and CD22+/+ (C57BL/6) mice in the spleen, lymph nodes or blood \[[@ppat.1008464.ref009]--[@ppat.1008464.ref012]\].

![CD22-deficient mice show impaired B cell numbers in the lung after *S*. *pneumoniae* infections.\
Numbers of neutrophils, eosinophils, T cells, alveolar macrophages, B2 cells and B1a cells were measured in the lungs (A-F) and in the spleen (G,H) by flow cytometry at various time points up to 48 hours (h) after intranasal S. pneumoniae infection. Cell populations were determined with the shown markers. Significant differences between C57BL/6 and CD22-/- mice at each time point are shown. Data are means ± SEM. \* = p\<0.05, \*\* = p\<0.01, \*\*\* = p\<0.001. Significant increase over time of (A) neutrophil numbers observed in the lungs of control and CD22-deficient mice (p\<0.01), as well as of (B) eosinophils in the lungs of control (p\<0.001) and CD22-deficient mice (p\<0.01), of (C) T cells in the lungs of control (p\<0.01) and CD22-deficient mice (p\<0.01), of (D) macrophages in the lungs of control (p\<0.01) and CD22-deficient mice (p\<0.05), of (E) B2 cells in the lungs of control (p\<0.001) and CD22-deficient mice (p\<0.001) and of (F) B1a cells in the lungs of control (p\<0.01) and CD22-deficient mice (p\<0.01).](ppat.1008464.g004){#ppat.1008464.g004}

We examined whether impaired B cell homing to the lung or impaired cellular proliferation/ survival in the lung is the mechanism responsible for the B-cell defect after *S*. *pneumoniae* infections. For this purpose, lung homing assays after cellular transfers with WT and CD22-/- B cells were performed. Splenic cells of C57BL/6 or CD22-/- mice were labelled with the dyes CFSE or CTV, respectively, then mixed in a 1:1 ratio and co-injected i.v. into C57BL/6 recipient mice ([Fig 5A](#ppat.1008464.g005){ref-type="fig"}). In order to avoid an influence of the dyes, in some experiments the dyes were also swapped between the splenocytes of the two strains, without any change of results. The recipient mice were analysed at an early time point (2h after cell transfer) and at two later time points (24h and 48h). While there was no difference between WT and CD22-/- B cell numbers detected in the lungs of recipients after 2 h or 24 h, there was a clear reduction of B cell numbers at 48 h ([Fig 5B](#ppat.1008464.g005){ref-type="fig"}). In contrast, T cell numbers of both donors in the lungs were similar. Also no differences of B cell numbers of both donors in the spleen of recipient mice were observed ([Fig 5B](#ppat.1008464.g005){ref-type="fig"}). This shows that the initial homing of CD22-/- B cells to the lungs is not impaired, however CD22-/- B cells seem to show less retention in the lung. By comparison of the dilution of CFSE or CTV, respectively, we did not observe different proliferation of WT and CD22-/- B cells. We therefore suggest that the reduced CD22-/- B cell numbers in the lung at 48h may indicate an impaired survival.

![Reduced CD22-/- B cell numbers in the lungs of recipient mice detected 48 hours after cellular transfer.\
Flow cytometric analysis of lung and spleen cells from C57BL/6 mice injected i.v. with CFSE labelled C57BL/6 WT splenocytes and CTV labelled CD22^-/-^ splenocytes (or vice versa) in a 1:1 mix. At various time points lungs and spleens were collected and stained for B220 and CD3. A) Gating strategy for the analysis of the proportion of WT and CD22^-/-^ B and T cells found in the lung of recipient WT mice. B) Analysis of the percentage of WT and CD22^-/-^ B and T cells found in the lung and spleen 2, 24 and 48 hours after i.v. injection. The proportion of WT and CD22^-/-^ donor cells is displayed as the ratio of the percentage of CTV or CFSE-positive B or T cells found in the lung or spleen of recipient mice, divided by the percentage of CTV or CFSE-positive B or T cells injected (input) x 100. Bar diagrams show a summary of 11 independent experiments with 8 recipient mice per time point. Statistics were done with a two-tailed *t* test. \*\* = p\<0.01.](ppat.1008464.g005){#ppat.1008464.g005}

CD22-deficient mice have an impaired population of GM-CSF producing IRA B cells in the lung, both after *S. pneumoniae* or *E. coli* infections {#sec006}
-----------------------------------------------------------------------------------------------------------------------------------------------

In order to further examine the mechanism for the high susceptibility of CD22-/- mice to pneumococcal infection, secreted IgM and GM-CSF was measured in the bronchoalveolar lavage (BAL) of infected mice, because natural IgM that is produced by GM-CSF secreting B1a--like cells has been shown to be crucial for protective anti-bacterial responses in the lung \[[@ppat.1008464.ref013]\]. We found lower IgM levels in the BAL of CD22-/- mice compared to the C57BL/6 control at early time points (3 hours and 6 hours) (p\<0.01) after infection ([Fig 6A](#ppat.1008464.g006){ref-type="fig"}). Also, lower GM-CSF levels were detected 3 hours after infection in the BAL of CD22-/- mice compared to the control (p\<0.05) ([Fig 6C](#ppat.1008464.g006){ref-type="fig"}), whereas IgM and GM-CSF concentrations in the blood were similar in CD22+/+ and CD22-/- mice ([Fig 6B and 6D](#ppat.1008464.g006){ref-type="fig"}). IgM and IgG levels were also determined in CBA/Ca and BALB/c mice after pneumococcal infections. Here only a mild reduction of IgM in the BAL of CBA/Ca mice was detected at 24 hours after infection, while the IgG levels were similar in both types of mice ([S4 Fig](#ppat.1008464.s004){ref-type="supplementary-material"}).

![IgM and GM-CSF levels in the BAL fluid of CD22-deficient mice after *S*. *pneumoniae* infections.\
IgM (A, C) and GM-CSF (B, D) levels were measured by ELISA in BAL fluid of the lung (A, B) and in blood serum (C, D) after intranasal *S*. *pneumoniae* infection. Data are the means ± SEM. The p-values (\* = p\<0.05, \*\* = p\<0.01, \*\*\* = p\<0.001) were obtained with two-tailed *t*-test. Significant increase of IgM levels in the BAL fluid in control mice between 0 and 6 hours post-infection (p\<0.01), but no significant change in IgM levels in the BAL fluid of CD22-/- mice (p\>0.05). No significant changes were observed over the time course of the infection in the blood serum IgM levels of test and control groups (p\>0.05). In the analysis of GM-CSF in the BAL fluid, it was observed a significant increase between 0 and 6 hours post-infection in control mice (p\<0.05), but not in the CD22 knock-out mice (p\>0.05). Over the time course of infection, the GM-CSF levels have significantly increased in the blood serum of control mice (p\<0.05), although no significant change in the GM-CSF levels of CD22-/- mice (p\>0.05).](ppat.1008464.g006){#ppat.1008464.g006}

GM-CSF can be produced by several cell types \[[@ppat.1008464.ref014]\], therefore we wanted to determine the source of GM-CSF produced by B cells in the lung. GM-CSF producing B cells (IRA B cells) are known to be recruited to the lung after bacterial infections \[[@ppat.1008464.ref013]\]. To determine IRA B cells in the lung, C57BL/6 control and CD22-/- mice were infected with *S*.*pneumoniae* intranasally (1 x 10^5^ CFU, a lower than normal dose to obtain better survival) and analysed 72 hours after infection. At this time point IRA B cells in the lung (defined as CD19+, CD43+ CD93+) were determined. [Fig 7A](#ppat.1008464.g007){ref-type="fig"} shows the flow cytometry data and gating strategy for lung IRA B cells. CD22-/- had significantly lower levels of IRA B cells in the lungs (p\<0.05) ([Fig 7B](#ppat.1008464.g007){ref-type="fig"}). Also, the number of GM-CSF+ IRA B cells was significantly lower (p\<0.05), and there was at least a tendency to lower intracellular IgM+ IRA B cell numbers in the lungs CD22-/- mice compared to the C57BL/6 ([Fig 7B](#ppat.1008464.g007){ref-type="fig"}). In contrast, this difference was not found in the spleen ([Fig 7C](#ppat.1008464.g007){ref-type="fig"}).

![CD22-deficient mice have a lower number of GM-CSF producing IRA B cells in the lungs after pneumococcal infections.\
C57BL/6 control and CD22-/- mice (C57BL/6 background) were infected with 1 x 10^5^ CFU *S*. *pneumoniae* intranasally and were analysed 72 hours after infection. (A) IRA B cells (MHCII+, CD19+, CD43+, CD93+) were identified in lung and spleen, as indicated for lung. (B) IRA B cells and GM-CSF+ and intracellular IgM+ (IgMic+) B cells were quantified in the lung. (C) GM-CSF+ and intracellular IgM+ (IgMic+) B cells were quantified and in the spleen. For B) and C) total cell numbers were calculated as percentage of total leukocyte numbers. \* = p\<0.05. n = 7 (C57BL/6) or n = 8 (CD22-/-) mice were used. A representative of two experiments is shown.](ppat.1008464.g007){#ppat.1008464.g007}

IRA B cells were first described after *E*. *coli* infections of the lungs of mice \[[@ppat.1008464.ref013]\]. In order to use the same model in which IRA B cells were first detected, CD22-/- and C57BL/6 control mice were intranasally infected with *E*. *coli*. Similar to pneumococcal infections, intranasal infection with *E*. *coli* resulted in a significantly higher mortality (p\<0.001) and higher CFUs in CD22-/- mice (p\<0.001) ([Fig 8A and 8B](#ppat.1008464.g008){ref-type="fig"}). As we wanted to determine IRA B cells after *E*.*coli* infection with a protocol consistent with a previous report \[[@ppat.1008464.ref013]\], we did intratracheal infections with *E*.*coli*. All CD22-/- mice and the C57BL/6 controls survived intratracheal infection for at least 72 hours post-infection with *E*. *coli*. 72 hours after intratracheal infection with *E*. *coli* CD22-/- mice had significantly lower levels of IRA B cells in the lungs (p\<0.01) ([Fig 8C](#ppat.1008464.g008){ref-type="fig"}). Also, the number of GM-CSF+ or intracellular IgM+ IRA B cells was significantly lower (p\<0.01, p\<0.05, respectively) in the lungs of CD22-/- mice compared to the C57BL/6 mice ([Fig 8C](#ppat.1008464.g008){ref-type="fig"}). In the spleen, CD22-/- mice infected with *E. coli* also showed lower intracellular IgM+ IRA B cells, while the number of GM-CSF+ IRA B cells was not significantly different ([Fig 8D](#ppat.1008464.g008){ref-type="fig"}). We conclude that both after *S*.*pneumoniae* and *E. coli* infections CD22-/- mice have an impaired IRA B cell population in the lung, with impaired GM-CSF and IgM production, and therefore lack an important mechanism for protection against bacterial infections.

![CD22-deficient mice show a high susceptibility to *E*. *coli* intranasal infection and have a lower number of GM-CSF producing IRA B cells in the lungs.\
Mice were infected with *E*. *coli* intranasally (A, B) or intratracheally (C-D). (A) Survival of intranasally infected mice was monitored for 7 days post-infection. (B) Number of bacteria per ml of BAL fluid at time of death. (C-D) 72 hours after *E*. *coli* infection, IRA B cells were identified in (C) lung and (D) spleen, similarly as shown in [Fig 7A](#ppat.1008464.g007){ref-type="fig"}. Within this IRA B cell population, GM-CSF+ and intracellular IgM+ (IgMic+) B cells were quantified in the lung (C) and in the spleen (D). For C) and D) total cell numbers were calculated as percentage of total leukocyte numbers. \* = p\<0.05, \*\* = p\<0.01, \*\*\* = p\<0.001. One representative of two experiments is shown.](ppat.1008464.g008){#ppat.1008464.g008}

Discussion {#sec007}
==========

Here we report the surprising finding that CD22, a member of the sialic acid binding Ig-like Siglec family of lectins, is an essential factor in innate resistance to pneumococcal disease. This is a surprising finding because CD22 has so far only been described as a negative regulator of B cell signalling \[[@ppat.1008464.ref005], [@ppat.1008464.ref006]\].

Within the B cell population, B-1 cells are known to play a critical role in response to pneumococcal infections. B-1 cells are innate-like B cells and the B-1a cell subpopulation produces phosphorylcholine- specific IgM, which serves as a first line defence against pneumococci \[[@ppat.1008464.ref015], [@ppat.1008464.ref016]\]. Upon bacterial lung infection of mice with pneumococci, B-1a cells from the peritoneal cavity can relocate to the lung where they produce protective IgM. It has been shown that a particular B cell subset producing the cytokine GM-CSF, called IRA B cells (for innate-response activator B cells) is crucial for this response \[[@ppat.1008464.ref013]\]. Now we can conclude that CD22 is a critical factor for the contribution of B cells to the innate anti-pneumococcal responses.

The role of CD22 in immune responses previously has been studied with different classes of model antigens. Although thymus-independent antibody responses of CD22-deficient mice to antigens, such as NP-ficoll, are impaired due to missing or non-functional B cell subpopulations, such as marginal zone (MZ) or B-1b B cells \[[@ppat.1008464.ref017], [@ppat.1008464.ref018]\], thymus-dependent antibody responses to protein antigens are largely normal \[[@ppat.1008464.ref009]--[@ppat.1008464.ref012]\]. The loss of such a negative regulator would be anticipated to lead to stronger B cell responses. Consistent with this notion, CD22-deficient mice show signs of B cell hyperactivation and can develop autoimmune diseases, particularly when in combination with deficiency of another B-cell Siglec, Siglec-G \[[@ppat.1008464.ref019], [@ppat.1008464.ref020]\].

The role of CD22 in infections has not been widely studied but to be in line with the observations on autoimmunity \[[@ppat.1008464.ref019], [@ppat.1008464.ref020]\], it might be predicted that loss of CD22 would not have a negative impact on the outcome of acute infection. Hence, a single publication reported CD22^--/--^mice have normal morbidity and mortality after staphylococcal infection \[[@ppat.1008464.ref021]\]. In that study, injections with staphylococci were done intraveneously, which might explain the different results to intranasal pneumococcal infections reported here. Conversely, CD22 has been shown to play a role in controlling a viral infection. CD22-deficient mice are more susceptible to West Nile Virus (WNV) infection, after which there was normal anti-WNV antibody production but decreased WNV-specific CD8^+^ T cell responses compared to wild type mice, including decreased lymphocyte migration into the draining lymph nodes \[[@ppat.1008464.ref022]\].

It seems that a crucial B cell subpopulation is affected by the CD22-deficiency. After both pneumococcal and *E. coli* lung infections, CD22-deficient mice have a strongly reduced population of GM-CSF producing IgM secreting B cells in the lung. It has been shown, that in microbial airway infections, pleural B cells migrate to the lung where they produce protective IgM \[[@ppat.1008464.ref015], [@ppat.1008464.ref016]\]. GM-CSF producing IRA B cells are crucial for this process, as mice with a B-cell specific GM-CSF deficiency fail to secrete protective IgM and therefore develop strong pneumonia \[[@ppat.1008464.ref013]\]. Our cell transfer experiments suggest not so much a lower homing of B cells to the lung, but rather that an impaired survival of B cells in the lungs of CD22-/- mice is responsible for this phenotype. CD22-deficient B cells show impaired survival *in vitro* and *in vivo* \[[@ppat.1008464.ref009], [@ppat.1008464.ref023]\], which may directly explain this lung phenotype.

In humans, attempts to find genetic factors contributing to susceptibility to pneumococcal disease so far have used candidate gene approaches. SNPs leading to a loss of the human CD22 protein have not been described so far. Systematic GWAS research on pneumococcal pneumonia susceptibility are lacking in the human, due to the difficulties in obtaining sufficient numbers of defined human subjects \[[@ppat.1008464.ref024]--[@ppat.1008464.ref026]\] and to the complex trait in susceptibility to infection, which is modulated by the individual's environment, age and gender \[[@ppat.1008464.ref027]\]. Here we have described that the *cd22* locus as a novel strong susceptibility locus for pneumococcal disease in mice. The human *cd22* locus appears not to have been investigated in candidate gene approaches and before now the *Cd22* gene would not be included in a typical candidate gene search for genetic factors in pneumococcal disease. The data presented here provide strong evidence that it should be a candidate gene for future studies on human pneumonia.

Materials and methods {#sec008}
=====================

Ethics statement {#sec009}
----------------

All animal experiments done at the University of Leicester were conducted in strict accordance with U.K. Home Office licence PPL60/4327. The University of Leicester Ethical Committee and the U.K. Home Office approved the experimental protocols. Infected animals were closely monitored for disease signs and mice were humanely culled immediately they reached the 'lethargic' endpoint, or at the end of the experiment. Where indicated in the text, some infection experiments were done at the University of Erlangen in accordance with the licence of the Regierung of Unterfranken.

Mice {#sec010}
----

Female BALB/cOlaHsd (abbreviated to BALB/c) and CBA/CaOlaHsd (CBA/Ca) were purchased from Harlan Laboratories (Bicester, UK) and were acclimatised for one week prior to use. Male and female CD22-deficient mice (Cd22tm1Lam) (on a pure C57BL/6 background) and control C57BL/6J mice (set up from littermates of CD22-deficient mice) \[[@ppat.1008464.ref009]\] were obtained from the University of Erlangen and then bred at the University of Leicester. Mice used for infection experiments were between 9 and 18 weeks of age and were age-matched.

Bacteria {#sec011}
--------

*Streptococcus pneumoniae* strain D39 (NCTC 7466), a mouse virulent serotype 2 strain, was used for infection studies. Bacteria were identified as pneumococci by the Gram stain, catalase test, α-haemolysis on blood agar and by optochin sensitivity. The presence of capsule was confirmed via the Quellung reaction. Before use in infection studies, bacteria were passaged through mice to standardise the inoculum and were stored at -80°C. When required, suspensions were thawed at room temperature and the inoculum prepared as described previously \[[@ppat.1008464.ref028]\]. *Escherichia coli* FDA strain Seattle 1946 (ATCC 25922) was used for intratracheal infection.

Infection of mice {#sec012}
-----------------

For intranasal infection, animals were lightly anaesthetised with 3% (v/v) isoflurane over oxygen, and an inoculum of 50μl containing 1x10^6^ CFU in PBS was administered drop by drop into the nostrils. Intranasal dosing of C57BL/6 strain, with an inoculum of 50μl containing 1x10^6^ CFU of *S*. *pneumoniae* strain D39 (serotype 2, NCTC 7466) in PBS. For experiment shown in [Fig 7](#ppat.1008464.g007){ref-type="fig"}, a dose of 1x10^5^ CFU of *S*. *pneumoniae* in PBS was used for intranasal infection. For intranasal infection of mice with *E*. *coli*, 5x10^6^ CFU in 50μl PBS was administered.

After infection, mice were frequently monitored and scored for visible signs of disease for 7 days (168 hours) according to the scheme of Morton and Griffiths \[[@ppat.1008464.ref029]\]. The time to reach the lethargic state was the experimental endpoint and was designated as "survival time". Animals that were alive after 7 days post-infection were considered to have survived the pneumococcal infection.

In experiments to determine survival, on reaching the endpoint or after 7 days, mice were deeply anaesthetized with 5% (v/v) isoflurane over oxygen, and then culled by cervical dislocation. In time course experiments, pre-determined groups of animals were culled, as above, at predetermined times. After confirmation of death, lung and spleen tissues were removed and cell suspensions prepared for bacterial counting or flow cytometry. Blood samples were taken by cardiac puncture under terminal anesthesia or by tail-bleeding to determine the number of bacteria and immune cells in the blood.

For intratracheal infection, mice were anesthetized with isoflurane and infected intratracheally with 5 × 10^6^ CFU *Escherichia coli* in a volume of 50 μl PBS with a 0.3ml syringe. Intratracheal *E*. *coli* infection of mice was done at the University of Erlangen.

Preparation of tissue homogenates {#sec013}
---------------------------------

Lung and spleen tissue were transferred into 10ml and 5ml, respectively, of sterile PBS, weighed, and then homogenised with an Ultra Turrax blender (Ika-Werke, Germany). Bacterial viable counts in homogenates were determined, followed by cell suspension preparation for flow cytometer analysis.

Determination of bacterial numbers in the tissues {#sec014}
-------------------------------------------------

The viable count of bacteria in blood, lungs and spleen were determined at the pre-chosen times after intranasal infection. Viable counts were determined by serial dilution in sterile PBS and plating on blood agar plates containing 5% (v/v) defibrinated horse blood (Oxoid). Plates were incubated in 5% (v/v) CO~2~ at 37°C overnight and then bacterial colony numbers counted the following day.

Flow cytometry {#sec015}
--------------

Cell suspensions were flushed through a 40μm cell strainer (BD Falcon) to remove tissue debris. Samples were centrifuged at 300 *g* for 5 min, at 4°C, discarding the supernatant. The cell pellet was resuspended in ACK lysis buffer (Invitrogen) and incubated for 5 minutes, at room temperature, for lysis of erythrocytes. Once the incubation step finished, cell suspension was quenched with 10 ml PBS + 3% (v/v) FCS and spun down at 300 *g* for 5 min, at 4°C. Mouse lung and spleen tissue cell pellets were resuspended with 1 ml PBS + 3% (v/v) FCS. Cell suspensions, at 1x10^8^ cells/ml, were incubated with anti-mouse CD16/CD32 blocking antibody (clone 2.4G2, BD Pharmingen) before addition of the specific antibodies. Cell surface markers were stained using a combination of fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, PE-Cy7- and allophycocyanin (APC)-conjugated monoclonal antibodies. Extracellular staining with monoclonal antibodies for CD4 (clone GK1.5, Biolegend), CD19 (clone 6D5, Biolegend), CD22 (clones OX-97 and Cy34.1, from Biolegend and BD, respectively), CD45 (clone 30-F11, Biolegend) and IgM (clone RMM-1, Biolegend) was performed according to the manufacturer's instructions. The presence of B-cell CD22 receptor in lung and spleen cells was assessed by staining with two monoclonal antibodies that bind to two different sites within domain two of the protein: clone OX-97 (Biolegend) and clone Cy34.1 (Becton Dickinson). In each experiment the appropriate isotype control monoclonal antibody and single staining controls were also included. Samples were analysed using a Becton Dickinson FACScalibur flow cytometer running CellQuest acquisition and analysed using FlowJo software (version 8.8.7, Tree Star).

Extraction and sequencing of genomic DNA {#sec016}
----------------------------------------

DNA from BALB/c and CBA/Ca mouse strains were sequenced for polymorphisms flanking the *Spir1* QTL \[[@ppat.1008464.ref002]\]. Firstly, DNA was extracted from tail tissue of mice, using a Nucleon kit (Gen-probe). Sequencing was then done at the Wellcome Trust Centre for Human Genetics by the High Throughput Genomics Group (UK), generating 8- to 10-fold coverage of a single lane of PE100nt per sample on the HiSeq2000. Paired-end Illumina reads from BALB/c and CBA/Ca mice were individually aligned to the reference genome (C57BL/6J, NCBIM37) using BWA. Detection of SNPs in each alignment was made using the Genome Analysis Toolkit (GATK) with default parameters. A filtering strategy was performed to identify high-confidence SNPs and reduce false positives. SNP sites that failed GATK's internal status check, quality \<300 or had an allele ratio \<0.8 were removed from further analysis. SNPs between CBA/Ca and BALB/c were then checked against the precompiled SNPs found in the 17 strains from the Mouse Genome Project ([http://www.sanger.ac.uk](http://www.sanger.ac.uk/)).

Primer design {#sec017}
-------------

Primers were designed for the *cd22* SNP identified from the sequencing data. Primers for pyrosequencing were designed using the PSQ Assay Design software (Biotage AB). Sets of three primers for each SNP were designed: one pair of primers for the PCR (one of which was biotinylated) and a sequencing primer for the pyrosequencing reaction. The minimum and maximum Tm for the PCR primers were 64 to 66°C. The sequencing primers were designed with a maximum distance of three bases from the SNP. Primers were manufactured by MWG-Biotech.

Extraction of genomic DNA and PCR {#sec018}
---------------------------------

For pyrosequencing of DNA from BALB/c and CBA/Ca mice, DNA was extracted from mouse-tail tissue, using the DirectPCR lysis reagent (Bioquote Limited). 180 μl DirectPCR lysis and 20 μl proteinase K solution (20 mg/ml) was added to each tail sample and incubated overnight at 55°C. After digestion, the samples were heated to 85°C for 45 min and centrifuged for 10 seconds. 10 μl PCR reactions were then set up using 5 μl Taq PCR master mix (Qiagen), 0.2 μl forward primer and 0.2 μl reverse primer (at 10 pmol/μl), 2.6 μl nuclease free water and 2 μl DNA (\~5 ng/μl). PCR reactions were run using the PCR program: 95°C for 5 min, followed by 45 cycles of 95°C for 15 sec, 60°C for 30 sec and 72°C for 15 sec. The final extension step was 5 min at 72°C.

Pyrosequencing {#sec019}
--------------

10 μl PCR product, 2 μl streptavidin-Sepharose beads (GE Healthcare), 38 μl binding buffer (Biotage) and 30 μl H~2~O were combined in each well of a 96-well plate and mixed vigorously on a plate shaker for 5 min. The PCR products were then prepared using a vacuum work table (Biotage AB). The biotinylated PCR products, attached to the filter probes of the vacuum apparatus, were immersed in 70% (v/v) ethanol for 5 seconds, denatured in PyroMark Denaturation solution (Biotage AB) for 5 sec (allowing only the biotin labeled strand of the PCR product to remain attached to the filter probes) and immersed in 1X PyroMark Wash buffer (Biotage AB) for 5 sec. The single-stranded PCR products were then re-suspended in a PSQ HS 96-well plate containing 0.5 μl sequencing primer (at 10 pmol/μl) and 11.5 μl annealing buffer (Biotage AB) per well. The plate was incubated at 80°C for 2 minutes to allow the sequencing primer to anneal to the single-stranded PCR product. The PSQ 96-well plate and a PSQ HS 96 capillary dispensing tip holder (Biotage AB) containing enzyme, substrate and dNTPs (PyroGold reagent kit Biotage AB), were placed into a PSQ HS 96 Pyrosequencer (Biotage AB). The data were analysed using the SNP software (Biotage AB).

Quantification of GM-CSF and IgM-producing B cells {#sec020}
--------------------------------------------------

72h after intratracheal infection with *E*. *coli*, organs were harvested and single cell suspensions obtained. For this, lungs were cut in small pieces and digested with 450 U/ml collagenase I (Sigma Aldrich), 125 U/ml collagenese IX (Sigma Aldrich), 60 U/ml hyaluronidase (Sigma Aldrich), 60 U/ml Dnase (Sigma Aldrich) in 20 mM Hepes pH7.4 (Thermo Scientific) for 1 hour at 37°C, while shaking. Spleens then were homogenised through a 40 μm nylon mesh. Total viable cell numbers were determined using trypan blue (Carl Roth). Lung homogenates and splenocytes were stained for cell surface markers for 20 minutes at 4°C, fixed for 20 minutes (BD Cytofix, BD Bioscience) at 4°C, washed and permeabilized for 20 minutes (BD Phosflow Perm Buffer III, BD Bioscience) at 4°C. Then cells were washed before staining with anti-GM-CSF and anti-IgM antibodies for 20 min at 4°C and washing twice. The following antibodies were used for flow cytometric analyses: anti-CD43-FITC (BD Biosciences), anti-CD93-BUV395 (BD Biosciences), anti-IgM-BV650 (BD Biosciences), anti-MHCII-BV711 (BD Biosciences), anti-CD45.2-BV786 (BD Biosciences), anti-CD19-BV421 (BD Biosciences), anti-GMCSF-PE (BD Biosciences), anti-IgM-PerCP Cy5.5 (BD Biosciences), IgG2a-PE (BD Biosciences), IgG2a-PerCP Cy5.5 (BD Biosciences). B cell populations were identified, as described previously \[[@ppat.1008464.ref030]\]. Data were acquired on a Celesta (BD Biosciences) flow cytometer and analyzed with FlowJo 10 (FlowJo LLC).

Cell transfer assay {#sec021}
-------------------

WT (C57BL/6)and CD22-/- splenocytes were isolated and labelled with CTV or CFSE (Molecular Probes, 1:1000 dilution in PBS, labelling for 10 minutes at room temperature), respectively. In half of the experiments splenocytes of the two strains were labelled after swapping the two dyes to exclude any effects of the dyes. Equal numbers of labelled donor cells (15--30x10^6^ cells per genotype) were mixed 1:1 and injected intravenously into C57BL/6 WT recipients. After 2, 24 and 48 hours lungs and spleens of the recipient mice were isolated, lungs were digested with Collagenase D (50mg/ml) / DNAse I (50mg/ml) for 30 minutes at 37°C, single cell suspensions of the lungs and spleens were produced and erythrocyte lysis was performed. Lung and spleen cells were stained for flow cytometry with anti-B220 and anti-CD3 antibodies (Biolegend) to identify B220^+^ B cells and CD3^+^ T cells. Draq7 dye was used for live/dead staining. The proportion of WT and CD22^-/-^ donor cells was evaluated by calculation of the ratio: percentage of CTV or CFSE-positive B or T cells found in the lung or spleen divided by the percentage of CTV or CFSE-positive B or T cells injected (input) x 100.

Statistics {#sec022}
----------

Data were analysed using a two-tailed unpaired Student *t* test or one- or two-way ANOVA, as appropriate. Survival data were analysed using Kaplan-Meier survival analysis. Results with p-values less than 0.05 were considered significant. Statistical analysis was performed with the aid of Graph Pad Prism (version 5.0b).

Supporting information {#sec023}
======================

###### The stop codon identified in the *cd22* gene of CBA/Ca does not occur in 37 inbred mouse strains from Jackson Laboratories.

The SNP found in the *cd22* gene in the CBA/CaOlaHsd inbred strain is located at position 7:30,877,586 (chromosome position highlighted in light blue), and is absent in all other sequenced strains. The SNPs in the figure have the following consequences: T (dark red) stop gained; A, C, G and T (light red), NMD transcript variant; A, G and T, (yellow) missense/initiator codon variant; A and C (green), synonymous/stop retained variant. The asterisk symbol on the SNP indicate that the SNP was observed in multiple sequences. Exon 4 SNPs (blue highlighted box with an arrow indicating the reverse orientation) are located between SNP positions 7:30,877,522--30,877,839. Data were collected from the Wellcome Trust's Sanger Institute website ([http://www.sanger.ac.uk](http://www.sanger.ac.uk/)).

(PDF)

###### 

Click here for additional data file.

###### B cells in CBA/Ca mice do not express CD22 as revealed by staining with Cy34.1 antibody.

Flow cytometric analysis of splenocytes and lung cells from BALB/c and CBA/Ca mice stained for CD19 and CD22 (MAb Cy34.1) 24 h after intranasal infection with *S. pneumoniae*.

(PDF)

###### 

Click here for additional data file.

###### B cell numbers in the lungs and spleen of CBA/Ca and BALB/c mice after pneumococcal infection.

Mice were intranasally infected with 1 x 10^6^ CFU and organs were collected at 0, 6, 12 and 24 hours post-infection. B cell numbers were determined by gating IgM-/+ CD19+ cells in lung (A) and spleen (B) by flow cytometry. Significant increase of B cells numbers over time (p\<0.01, from 0 to 24 hours p.i.) in the lung tissue of BALB/c mice (Figure A) and significant decrease in the spleen of BALB/c mice (p\<0.01). Examples of the 24 hours time point are shown in the top panels. Data are representative of two independent experiments with \> 4 mice per group. The p-values (\*\* = p\<0.01) were obtained with two-way ANOVA.

(PDF)

###### 

Click here for additional data file.

###### Slightly impaired IgM levels at 24 hours in BAL fluid of CBA/Ca mice after pneumococcal infection.

Mice were intranasally infected with 10^6^ CFU and BAL fluid was collected at 0, 6, 12 and 24 hours post-infection. Total IgM and IgG levels were determined by ELISA. Data are representative of two independent experiments with \> 4 mice per group. \*\* p\< 0.01 (two-way ANOVA).

(PDF)

###### 

Click here for additional data file.
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15 Aug 2019

Dear Dr. Nitschke,

Thank you very much for submitting your manuscript \"The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection\" (PPATHOGENS-D-19-01231) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Additionally, to enhance the reproducibility of your results, PLOS recommends that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods>

We hope to receive your revised manuscript within 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage, but if you have any concerns or questions, please do not hesitate to contact us.

Sincerely,

Dana J. Philpott

Associate Editor

PLOS Pathogens

Michael Wessels

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Grant McFadden

Editor-in-Chief
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

The reviewers were overall positive about the findings. One important aspect that should be addressed is to provide more convincing evidence that it is indeed B cell recruitment rather than in situ proliferation that is responsible for the phenotype. Moreover, the manuscript would be strengthened with data showing that in the pneumococcal model, there are also fewer IRA B cells (rather than just with the E coli infection).

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: The authors present convincing evidence that a SNP resulting in loss of function of CD22 largely accounts for the increased susceptibility of CBA/Ca mice to pneumococcal lung infection, relative to other inbred mouse strains. Moreover, CD22-/- mice in the C57BL/6 background exhibited enhances susceptibility relative to the wild type. Clues as to the underlying mechanism were also provided by data showing a defect in recruitment of IRA B cells, resulting in lower levels of GM-CSF and IgM. This study provides new information on the hitherto unrecognised role of CD22 in host resistance to bacterial infection and paves the way for further molecular epidemiological/GWAS studies, including in human populations. For this reason, it is an important contribution.

Reviewer \#2: In this manuscript, the authors describe an important and previously unrecognized role for CD22 in susceptibility of infection to Streptococcus pneumoniae. This works stems from an earlier report by the authors on a loci within CBA/Ca mice that causes high susceptibility to infection. This loci contains CD22, an important B cell inhibitory co-receptor, and it is found that a premature stop codon is located in the Cd22 gene within this strain that causes no functional CD22 to be expressed on their surface. To test if this loss of functional CD22 in CBA/Ca mice is responsible, the author carry out studies in C57BL/6 mice on a CD22+/+ and CD22-/- background. Studies in C57BL/6 mice support the authors' claim that CD22 is directly involved in susceptibility Streptococcus pneumoniae infection. The authors search for mechanism is far from complete, but they do reveal a key differences in B cell recruitment to the lung, supporting earlier reports of B cells being an important immune cell limiting Streptococcus pneumoniae infection in mice. The results are interesting, with many key questions remaining, but should be published after the points below are addressed:

Reviewer \#3: The paper by Fernandes et al., seeks to describe the role of CD22 in susceptibility to pneumococcal disease. The authors hypothesis is that a point mutation in CD22 in CBA mice is the cause of their susceptibility to pneumococcal disease. They base their argument on the fact that CD22 KO mice are also susceptible to pneumococcal infection. This is an interesting hypothesis, however the main issue is that the data supporting this comes from the CD22 KO which is in the C57 background. Therefore, it is difficult to see how the authors can prove that CD22 really is the factor leading to susceptibility in CBA mice. Yes, there is an association i.e. it seems that in C57 mice lack of CD22 does lead to increased susceptibility to pneumococcal infection, but we need to see a direct link/proof in CBA mice. This is not provided, which is surprising as there are a number of experiments which could have been done to address this.

The only data provided from the CBA mouse background is the supplementary data which shows total B cells in lung and spleen tissue from CBA vs Balb/c mice. What is interesting is that there are no differences in B cells between these two strains of mice in lung or spleen, with the exception of 24hrs in lung B cells in CBA mice, but by this time the CBA mice already have high CFU levels in their blood based on previous papers and are dying from their infection. Indeed, CBA mice develop bacteremia as early as 6hrs post infection, hence the essential role of B cells in this mouse strain is not really supported.

See comments in additional exps that may strenghten paper.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: Page 8. Whilst the difference between C57BL/6 and CD22-/- mice in numbers IRA B cells in lungs after challenge with E. coli are convincing, it is a little puzzling why the authors did not attempt the same experiments in mice challenged with D39. It would be preferable if such data were included in the manuscript.

Reviewer \#2: (No Response)

Reviewer \#3: \[1\] It would be good to see IgM and IgG levels (including subsets) in CBA vs Balb/c mice (lungs and blood) following infection with pneumococci at the timepoints used (0, 6, 12, 24 etc).

\[2\] It would be good to see a more detailed B cell analysis, including subsets (B1, B2 etc) in above groups/times in lungs.

\[3\] Would be interesting to see adoptive transfer of B1 cells into CBA mice. If their susceptibility is due to a lack of these cells, then adoptive transfer would answer the question of whether this is true or not.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: Line 84. pneumoniae.

Line 92. LOD needs to be defined.

Line 93. The definition of QTL needs to be here rather than on line 99.

Line 176. It is not strictly correct to say there were no bacteria in the blood of infected C57BL/6 mice, as there was 1 culture-positive mouse at 12 h.

Line 187. should be Suppl Fig 2B.

Line 211. GM-CSF in blood was actually significantly higher in CD22-/- mice at 6 h, so perhaps this sentence needs to be qualified.

Fig. 4. The A, B, C and D labels are missing from the panels.

Reviewer \#2: 1. No direct evidence is provided to demonstrate a defect in B cell recruitment or strictly that it is CD22 expression on B cells that is the key factor. Accordingly, I have 4 inquiries:

a\) Can the authors rule out impaired proliferation of CD22-/- resident lung B cells?

b\) Is it known that B cells home to the lung in a similar manner as the Peyer's patches? Are HEVs involved? If so, it would certainly be worth discussing this similarity more directly. If not, it should be stated that a previously undiscovered homing mechanism would necessarily need to be at play.

c\) Can the authors rule out a role for DCs given that CD22 is known to be expressed on these cell types? Is there any known link between DCs and S. pneumoniae infection? In this respect, it is worth pointing out that Ma et al. (2012, J Virol) determined that loss of CD22 results in a significant decrease in several cytokines which was due to loss of CD22 in cDC2.

d\) Does S. pneumoniae express ligands of CD22 that could be contributing to these effects? Have the authors (or anyone previously) looked at staining of S. pneumoniae with CD22-Fc?

2\. For the study in Ref19, it would be worth discussing any possible differences in: a) route of administration, b) strain background, c) primary site of infectivity between Staphylococcal and Streptococcal infection between studies.

3\. Please provide suitable ref for the statement on Lines 146-148 about antibody specificity.

4\. Lines 224-226: Data not shown?

5\. Lines 228-237: Assume this is referring to intranasal infection? Since the experiment described directly above is intratracheal, it should be clearly stated.

6\. Are there any reported SNPs in humans that result in loss of CD22 protein or loss of functional CD22? Worth mentioning either way in the discussion.

7\. Typos:

Line 222: Type: C22

Line171: CD22 -/- to CD22-/-

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

10.1371/journal.ppat.1008464.r002
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Submitted filename: point by point response2.pdf
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Click here for additional data file.
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15 Feb 2020

Dear Dr. Nitschke,

Thank you very much for submitting your manuscript \"The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection\" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Thank you for submitting your work to PLOS Pathogens. The reviewers were mostly satisfied with the revision; there were some minor points to be addressed outlined by Reviewer 2. Please make these changes with respect to data presentation (individual data points) as well as addressing the comments highlighted by Reviewer in the text of the paper.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. 

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Dana J. Philpott

Associate Editor

PLOS Pathogens

Michael Wessels

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Thank you for submitting your work to PLOS Pathogens. The reviewers were mostly satisfied with the revision; there were some minor points to be addressed outlined by Reviewer 2. Please make these changes with respect to data presentation (individual data points) as well as addressing the comments highlighted by Reviewer in the text of the paper.

Reviewer Comments (if any, and for reference):

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: The authors have satisfactorily addressed the issues raised in my original review.

Reviewer \#2: The issues brought up by the reviewers have mostly be addressed in a satisfactory manner. My final comments more about presentation and description of the data.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: N/A

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: N/A

Reviewer \#2: 1) It would strengthen the presentation to show individual data points in the bar graphs.

2\) i) In the new adoptive transfer data, the authors describe it as \'migration\'. While I am admittedly not an expect in this area, I think migration refers more to movement towards a signal, which may be more appropriate during infection. Since these particular experiments were carried out in healthy mice, I believe homing is the more correct term.

ii\) They describe infer that the adoptive transfer experiment provides insight into \'proliferation in the lung\'. I do not see evidence that they examined this aspect (which could have been done in the context of fluorescence dilution). It appears that they have only investigated homing and retention. Wording to describe this in the text should be modified appropriately.

3\) lines 46 and 113- it is written \'a lack of B cells\' in CD22-null mice post infection. While B cell population in the lungs CBA/Ca mice is significantly reduced after bacterial inoculation, there are a few that were observed. I think it is an overstatement to say that these mice lack the B cells.

4\) In Figures 7B/7C and 8C/8D, the authors should report if these are normalized (e.g. per mg tissue).

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

[Figure Files:]{.ul}

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}
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Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.
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Dear Dr. Nitschke,

We are delighted to inform you that your manuscript, \"The B-cell inhibitory receptor CD22 is a major factor in host resistance to *Streptococcus pneumoniae* infection,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.
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